CRP and chronic kidney disease: In contrast, in SHR-CRP rats, empagliflozin benefit was based on reduced renal inflammation and oxidative stress [23], which is in line with the findings of Ali et al. [18], who also demonstrated a reduction in renal inflammation and ROS production in adenine-induced CKD.